Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 6Pancreatic Neoplasms 4Neoplasms 4Glioma 4Sarcoma 3Prostatic Neoplasms 3Neoplasm Metastasis 3Melanoma 3Colorectal Neoplasms 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Pancreatic Ductal Adenocarcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Immunoglobulin Light-chain Amyloidosis 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Basal Cell 2Burkitt Lymphoma 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Smoking Cessation 1Skin Neoplasms 1Sarcoma, Ewing 1

Interventions

sugemalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pleural Effusion, Malignant × 30 days × Clear all
NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡